Natera (NTRA) Could Be 33% Undervalued Following FDA Breakthrough Device Designation

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

Natera, Inc. (NTRA) received FDA breakthrough designation for its multi-cancer blood test, which analyzes cell-free DNA. The FDA reviewed data from 12 cancer types, but no performance figures or submission timeline were disclosed. Natera shares rose to $403.62 on Friday.

Natera's multi-cancer early detection assay has received FDA Breakthrough Device Designation, a status for devices that show significant improvement over existing options. According to the FDA, this designation is meant to expedite the development and review process for innovative technologies.

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.

Natera (NTRA) announced its multi-cancer early detection assay received Breakthrough Device designation from the FDA. The assay analyzes cell-free DNA in blood to screen for multiple cancers, showing promising results in 12 cancer types.

Natera (NTRA) received FDA Breakthrough Device designation for its multi-cancer early detection assay, based on data from 12 cancer types. The designation signals regulatory progress but not yet marketing approval.